US Cutaneous Oncodermatology Management (USCOM): A Practical Algorithm

September 2021 | Volume 20 | Issue 9 | Supplement Individual Articles | 3ss | Copyright © September 2021

Published online September 1, 2021

Mario E. Lacouture MD,a Jennifer Choi MD,b Alice Ho MD,c Jonathan Leventhal MD,d Beth N. McLellan MD,e Anneke Andriessen PhD,f Maxwell B. Sauder MD,g Edith Mitchell MDh

aOncodermatology, Memorial Sloan Kettering Cancer Center, New York, NY
bOncodermatology Program, Department of Dermatology, Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
cRadiation Oncology, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, New York, NY
dOncodermatology, Smilow Cancer Hospital at Yale, New Haven, CT
eMontefiore's Division of Dermatology and Montefiore Einstein Center for Cancer Care; Dermatology, Jacobi Medical Center, New York, NY fRadboud UMC, Nijmegen and Andriessen Consultants, Malden, The Netherlands
gOncodermatology, Princess Margaret Cancer Centre, Pigmented Lesion Clinic, Toronto Dermatology Disparities; Gastrointestinal Centre, Toronto, ON, Canada
hCenter to Eliminate Cancer Disparities, Gastrointestinal Oncology, Thomas Jefferson University Hospital and Jefferson Methodist Hospital, Philadelphia, PA

cutaneous drug reactions: An updated review on risks associated with anticancer targeted therapy or immunotherapy. J Immunol Res. 2018;(1):5376476
29. Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv119-iv142.
30. Weber JS, K hler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30(21):2691-7.
31. Sibaud V. Dermatologic Reactions to immune checkpoint inhibitors : skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19(3):345-361.
32. Curry JL, Tetzlaff MT, Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44(2):158-76.
33. Schaberg KB, Novoa RA, Wakelee HA, et al. Immunohistochemical analysis of lichenoid reactions in patients treated with anti-PD-L1 and anti-PD-1 therapy. J Cutan Pathol. 2016;43(4):339-46.
34. Voudouri D, Nikolaou V, Laschos K, et al.Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer. 2017;41(6):407-12.
35. Rofe O, Bar-Sela G, Keidar Z, et al. Severe bullous pemphigoid associated with pembrolizumab therapy for metastatic melanoma with complete regression. Clin Exp Dermatol. 2017;42(3):309-12.
36. Vivar KL, Deschaine M, Messina J, et al. Epidermal programmed cell deathligand 1 expression in TEN associated with nivolumab therapy. J Cutan Pathol. 2017;44(4):381-84.
37. Falk SJ, Bober S. Vaginal health during breast cancer treatment. Curr Oncol Rep. 2016;18(5):32. Doi: 10.1007/s11912-016-0517-x. 38. Baumgart J, Nilsson K, Stavreus-Evers A, et al. Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer. Am J Obstet Gynecol. 2011;204(1):26.e1-7.
39. Yagasaki K, Komatsu H, Hamamoto Y. Targeted therapy-induced facial skin toxicities: Impact on quality of life in cancer patients. Asia Pac J Oncol Nurs. 2018;5(2):172-177.
40. Freites-Martinez A, Chan D, Sibaud V, et al. Assessment of quality of life and treatment outcomes of patients with persistent postchemotherapy alopecia. JAMA Dermatol. 2019;155(6):724-728.
41. Kao S, Friedman A. Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies. Oncology Issues. 2018;33(6):64-75.
42. Della Corte CM, Morgillo F. Early use of steroids affects immune cells and impairs immunotherapy efficacy. ESMO Open 2019;4e000477. http://dx.doi. org/10.1136/esmoopen-2018-000477
43. Clabbers JMK, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJM, et al. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016;24:513–21.[PMC free article] [PubMed] [Google Scholar]
44. Grimes PE. A closer look at the role of the dermatologist in championing total women's health through the dermatology gateway. Int J Women Dermatol. 2018;4:189-192.
45. Lucas AS, Ciccolini K. The role of oncodermatology in care of patients receiving cancer therapy. Seminars in Oncology Nursing. 2017;22(4):393-401.
46. Berger A, Regueiro C, Hijal T et al. Interest of supportive and barrier protective skin care products in the daily prevention and treatment of cutaneous toxicity during radiotherapy for breast cancer. Breast Ca: Basic Clin Research Vol. 2018;12:1-7.
47. Wohlrab J, Luftner D, Johne A, et al. The advantage of a proactive, barrier-protective, supportive skin care in patients with breast cancer on chemotherapy. Oncology. 2011;34:1144-1149.
48. Lüftner D, Dell'Acqua V, Selle F, et al. Evaluation of supportive and barrierprotective skin care products in the daily prevention and treatment of cutaneous toxicity during systemic chemotherapy. Onco Targets Ther. 2018 Sep 17;11:5865-72.
49. Common Terminology Criteria for Adverse Events (CTCAE) v5.0 April 1, 2018. ctc.htm
50. Sauder MB, Andriessen A, Claveau J, Hijal T, Lynde CW. Canadian skin management in oncology (CaSMO) algorithm for patients with oncology treatment-related skin toxicities. Skin Ther Letter. 2021 S March (3):1-10.
51. Schachner LA, Andriessen A, Benjamin L et al. Do antimicrobial resistance patterns matter? An algorithm for the treatment of patients with impetigo. J Drugs Dermatol. 2021;20(2):134-142. doi:10.36849/JDD.2021.5475
52. Kwong BY. Outcomes of embedding dermatologic care within oncology practices for patients with cancer. JAMA Dermatol. 2020;156(10):1051-1052. Doi:10.1001/jamadermatol.2020.1794.
53. Lynde CW, Tan J, Skotnicki S, Andriessen A, et al. Clinical insights about the role of skin pH in inflammatory dermatological conditions. J Drug Dermatol. 2019;18(12) Suppl 1:s221-s226. S1545961619S0213X/1/
54. Baumann BC, Verginadis II, Zeng C, et al. Assessing the validity of clinician advice that patients avoid the use of topical agents before daily radiotherapy treatments. JAMA Oncol. 2018;4(12):1742-1748. doi: 10.1001/ jamaoncol.2018.4292
55. Salzmann M, Marm  F, Hassel JC. Prophylaxis and management of skin toxicities. Breast Care. 2019;14:72-77.
56. Baumann BC, Zeng C, Freedman GM, et al. Avoiding antiperspirants during breast radiation therapy: myth or sound advice? Radiother Oncol. 2017;124(2):204-207. doi:10.1016/j.radonc.2017.06.021 [PubMed] [CrossRef] [Google Scholar]
57. Sander M, Sander Mi, Burbidge T, Beecker J. The efficacy and safety of sunscreen use for the prevention of skin cancer. Can Med Assn J. 2020;192(12):E1802-8. Doi:10.1503/cmaj.201085
58. Cole C, Shyr T, Ou-Yang H. Metal oxide sunscreens protect skin by absorption, not by reflection or scattering. Photodermatol Photoimmunol Photomed. 2016;32(1):5-10. DOI:10.1111/phpp.12214. Epub 2015 Nov10, PMID: 26431814.
59. Gabros S, Nessel TA, Zito PM. Sunscreens and photoprotection. [Updated 2020 April 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: NBK537164/
60. Gandhi M, Oishi K, Zubal B, et al. Unanticipated toxicities from anticancer therapies: survivors' perspectives. Support Care Cancer. 2010;18(11):1461- 1468.
61. Zurfley F, Mostow EN. Association between the use of a physician extender and dermatology appointment wait times in Ohio. JAMA Dermatol. 2017;153(12):1323-1324.
62. Crews J. 2019 (4). 20190416/telemedicine-in-oncology-virtual-solution-to-a-very-realproblem.
63. Naidoo J. A multidisciplinary toxicity team for cancer immunotherapy-related adverse events. J Natl Compr Canc Netw 2019;17(6):712-720.


Mario E. Lacouture MD